FIRE-9 – PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer

Table 1 Trial medication (guidance for administration)

Drug	Dose/ Potency	Duration of administration^c	Route of Administration	Day(s) of application
mFOLFOX-6 regimen:
Oxaliplatin	85 mg/m²	2 h	IV infusion	d1 of each chemotherapy cycle
Leucovorin	400 mg/m²	1-2 h	IV infusion
5-FU^a	400 mg/m² bolus^b 2400 mg/m²	2–5 min 46 h	IV infusion IV infusion
mFOLFOXIRI regimen:
Oxaliplatin	85 mg/m²	2 h	IV infusion	d1 of each chemotherapy cycle
Irinotecan	150 mg/m²	90 min	IV infusion
Leucovorin	400 mg/m²	1-2 h	IV infusion
5-FU^a	2400 mg/m²	46 h	IV infusion

^ain DPD mutation carriers with a CPIC activity score of 1.0–1.5, 5-FU Dosage should be reduced by 50%
^badditional 400 mg/m² bolus is permitted
^cinfusion rates of chemotherapeutical components represent recommendations but might be modified according to local standards

ISSN: 1471-2407